AI assistant
GALECTIN THERAPEUTICS INC — Director's Dealing 2018
Jun 5, 2018
33422_dirs_2018-06-05_984bcb47-e630-4337-b8b4-df42e9568e6a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2018-06-01
Reporting Person: 10X Fund, L.P. (10% Owner)
Reporting Person: 10X Capital Management, LLC (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-06-01 | Common Stock | S | 41907 | $5.12 | Disposed | 3161693 | Indirect |
| 2018-06-04 | Common Stock | S | 8093 | $5.13 | Disposed | 3119786 | Indirect |
Footnotes
F1: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.